NASDAQ:SUPNSupernus Pharmaceuticals Stock Price, Forecast & News

Supernus Pharmaceuticals' stock was trading at $16.15 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SUPN shares have increased by 49.3% and is now trading at $24.12. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Supernus Pharmaceuticals.

Supernus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Supernus Pharmaceuticals.

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) posted its earnings results on Tuesday, May, 5th. The specialty pharmaceutical company reported $0.40 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.30 by $0.10. The specialty pharmaceutical company had revenue of $94.98 million for the quarter, compared to the consensus estimate of $84.01 million. Supernus Pharmaceuticals had a net margin of 28.90% and a return on equity of 20.31%. Supernus Pharmaceuticals's quarterly revenue was up 11.1% on a year-over-year basis. During the same period last year, the company earned $0.34 earnings per share. View Supernus Pharmaceuticals' earnings history.

6 Wall Street analysts have issued 12 month target prices for Supernus Pharmaceuticals' stock. Their forecasts range from $23.00 to $50.00. On average, they anticipate Supernus Pharmaceuticals' stock price to reach $30.50 in the next twelve months. This suggests a possible upside of 26.5% from the stock's current price. View analysts' price targets for Supernus Pharmaceuticals.

Media stories about SUPN stock have been trending negative on Monday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Supernus Pharmaceuticals earned a media sentiment score of -2.6 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutSupernus Pharmaceuticals.

Supernus Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totaling 3,960,000 shares, a decline of 10.6% from the April 30th total of 4,430,000 shares. Based on an average daily trading volume, of 684,000 shares, the short-interest ratio is presently 5.8 days. Currently, 7.8% of the company's stock are sold short. View Supernus Pharmaceuticals' Current Options Chain.

Some companies that are related to Supernus Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), AbbVie (ABBV), GW Pharmaceuticals PLC- (GWPH), Pfizer (PFE), Exelixis (EXEL), Netflix (NFLX), Cara Therapeutics (CARA) and Corcept Therapeutics (CORT).

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Supernus Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Morgan Stanley (2.17%), Morgan Stanley (2.17%), Rice Hall James & Associates LLC (1.80%), Geode Capital Management LLC (1.44%), Aristotle Capital Boston LLC (1.41%) and Ashford Capital Management Inc. (1.10%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, Jack A Khattar, Padmanabh P Bhatt and Stefan KF Schwabe. View institutional ownership trends for Supernus Pharmaceuticals.

SUPN stock was sold by a variety of institutional investors in the last quarter, including Mackay Shields LLC, Wells Fargo & Company MN, Loomis Sayles & Co. L P, Deutsche Bank AG, Ashford Capital Management Inc., Aequim Alternative Investments LP, Mutual of America Capital Management LLC, and State Board of Administration of Florida Retirement System. View insider buying and selling activity for Supernus Pharmaceuticals.

SUPN stock was bought by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Morgan Stanley, Morgan Stanley, Voloridge Investment Management LLC, Pictet Asset Management Ltd., and S&T Bank PA. View insider buying and selling activity for Supernus Pharmaceuticals.

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SUPN stock can currently be purchased for approximately $24.12.

Supernus Pharmaceuticals has a market capitalization of $1.27 billion and generates $392.76 million in revenue each year. The specialty pharmaceutical company earns $113.06 million in net income (profit) each year or $2.10 on an earnings per share basis. Supernus Pharmaceuticals employs 448 workers across the globe.

The official website for Supernus Pharmaceuticals is www.supernus.com.

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]